(NASDAQ: VIRI) Virios Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Virios Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast VIRI's revenue for 2027 to be $360,701,160, with the lowest VIRI revenue forecast at $360,701,160, and the highest VIRI revenue forecast at $360,701,160. On average, 1 Wall Street analysts forecast VIRI's revenue for 2028 to be $710,232,717, with the lowest VIRI revenue forecast at $710,232,717, and the highest VIRI revenue forecast at $710,232,717.
In 2029, VIRI is forecast to generate $994,479,867 in revenue, with the lowest revenue forecast at $994,479,867 and the highest revenue forecast at $994,479,867.